LAGi-DEL

LAGi-DEL: sourced facts only. name: "LAGi-DEL binds directly to LAG-3 with a Kd of 97 nM (SPR) and 271 nM (MST) and disrupts the LAG-3/MHC-II interaction with an EC50 of 138 nM, the highest potency reported for a small molecule against LAG-3." [PMID:41016188]; target: "LAGi-DEL binds directly to LAG-3 with a Kd of 97 nM (SPR) and 271 nM (MST) and disrupts the LAG-3/MHC-II interaction with an EC50 of 138 nM, the highest potency reported for a small molecule against LAG-3." [PMID:41016188]; developer: "Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY, 10065, USA." [PMID:41016188]; modality: "LAGi-DEL, the first nanomolar small molecule LAG-3 inhibitor, identified through screening a 4.2-billion compound DNA-encoded chemical library (DEL)." [PMID:41016188]; stage: "Functionally, LAGi-DEL restores T cell activation, elevates IFN-γ secretion, and promotes immune-mediated killing in acute myeloid leukemia and lung cancer co-culture models, matching the efficacy of the FDA-approved antibody relatlimab." [PMID:41016188]